A Phase 2 interventional study of Gemcitabine and AG-013736 in Pancreatic Neoplasms, sponsored by Pfizer. Completed at 38 sites in 8 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2019-05-14.
Sponsored by Pfizer · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 25 studies in Pancreatic Neoplasms by Pfizer — 3 open to participants now, 4 under way, 1 of them phase 3. Pancreatic Neoplasms · Pfizer.
Among the 25 studies in Pancreatic Neoplasms by Pfizer, this one is the 9th largest by enrollment of the 24 interventional ones that give a count, is the only one that started in 2005, is one of 7 in phase 2, and was the 3rd registered.
3,897 studies on the registry are indexed under Pancreatic Neoplasms; 1,003 are open to participants now.
Browse Pancreatic Neoplasms studies →3 of the 25 studies in Pancreatic Neoplasms by Pfizer are open now, in 12 countries. Recruiting first, the newest first:
Pfizer · Sites in United States
Ages 18+
Pfizer · Sites in United States, Australia, Belgium and 18 more countries
Ages 18+
Pfizer · Sites in United States, Canada, China and 3 more countries
Ages 18+
By country, each count listing its studies:
Of the 743 Pancreatic Neoplasms studies recruiting now, 477 (64%) set no upper age limit and 151 (20%) stop at 75 or younger; 40 take children under 18; 59 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
25 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 15 · Phase 2 11 · Phase 3 2 · Phase 4 1
First in 1999; this study’s year is marked. 1 started in 2005.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 111 is above the median of 47 across 2,932 interventional studies indexed under Pancreatic Neoplasms.
Median enrollment 79 across the 24 interventional studies. Of the 21 that completed or were terminated, 12 (57%) have results posted.
This tab as a report to print or save as PDF → With an account.
Pfizer is the lead sponsor of 3,337 studies on the registry; 150 are open to participants now.
Of its 601 completed or terminated interventional studies of FDA-regulated products, 392 (65%) have results posted.
None of the studies under way reaches primary completion within a year.
Among the 25 studies in Pancreatic Neoplasms by Pfizer, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This is a Phase 2 study being conducted at multiple centers in the United States, Europe and Canada. Patients having pancreatic cancer that is locally advanced or that has spread to other parts of the body (i.e., metastatic) are eligible to participate. Patients must have not had any prior systemic treatment for advanced disease. The purpose of the study is to test whether the angiogenesis inhibitor Axitinib [AG-013736] in combination with gemcitabine is an effective treatment for advanced pancreatic cancer vs. gemcitabine alone by overall survival.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).
Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.
Metastases
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Histologically or cytologically confirmed
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Brain metastases
Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).
Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Drug: Gemcitabine
Drug: AG-013736 · Drug: Gemcitabine
Gemcitabine 1000 mg/m\^2 30 minutes IV infusion on Day 1, 8 and 15 of each cycle, in cycles of 4 weeks
Axitinib (AG-013736) 5 mg tablet orally BID starting from Day 1 of Cycle 1, in cycles of 4 weeks.
Gemcitabine 1000 mg/m\^2 30 minutes IV infusion on Day 1, 8 and 15 of each cycle, in cycles of 4 weeks.
Overall Survival (OS)
Time in days from randomization to date of death due to any cause. OS was calculated as the death date minus the date of randomization plus 1. Death was determined from adverse event data (where outcome was death) or from follow-up contact data (where the participant current status was death).
Time frame: Baseline of Phase 2 to death or until at least 1 year after the randomization of the last participant
Dose Confirmation of Axitinib (AG-013736) on Basis of Number of Participants With Dose Limiting Toxicity (DLT)
Dose of axitinib (AG-013736) was confirmed if not more than 1 out of 6 participants experienced a DLT during first cycle. DLT included grade (Gr) 4 neutropenia or thrombocytopenia, greater than or equal to (\>=) Gr 3 anemia or non hematological toxicities for \>= 7 days (except alopecia) or \>= Gr 1 hemoptysis or \>=2 gram /24 hours proteinuria or inability to resume background chemotherapy or axitinib (AG-013736) dosing within 14 days of stopping due to treatment related toxicity.
Time frame: Phase 1 baseline up to Week 4
Dose Confirmation of Gemcitabine on Basis of Number of Participants With Dose Limiting Toxicity (DLT)
Dose of gemcitabine was confirmed if not more than 1 out of 6 participants experienced a DLT during first cycle. DLT included grade (Gr) 4 neutropenia or thrombocytopenia, greater than or equal to (\>=) Gr 3 anemia or non hematological toxicities for \>= 7 days (except alopecia) or \>= Gr 1 hemoptysis or \>=2 gram /24 hours proteinuria or inability to resume background chemotherapy or axitinib (AG-013736) dosing within 14 days of stopping due to treatment related toxicity.
Time frame: Phase 1 Baseline up to Week 4
Maximum Observed Plasma Concentration (Cmax) for Axitinib (AG-013736)
Time frame: 0 (pre-dose), 0.5, 1, 1.5, 2, 3.5, 4.5, 9.5, and 12.5 hours (hr) post-dose on Day 15 of Phase 1 Cycle 1
Area Under the Curve From Time Zero to 24 Hours [AUC (0-24)] of Axitinib (AG-013736)
AUC (0-24) = Area under the plasma concentration versus time curve (AUC) from time zero (pre-dose) to 24 hours (0-24).
Time frame: 0 (pre-dose), 0.5, 1, 1.5, 2, 3.5, 4.5, 9.5, and 12.5 hr post-dose on Day 15 of Phase 1 Cycle 1
Time to Reach Maximum Observed Plasma Concentration (Tmax) of Axitinib (AG-013736)
Tmax was based on the actual time points when the samples were collected.
Time frame: 0 (pre-dose), 0.5, 1, 1.5, 2, 3.5, 4.5, 9.5, and 12.5 hr post-dose on Day 15 of Phase 1 Cycle 1
Plasma Decay Half-life (t1/2) of Axitinib (AG-013736)
Plasma decay half-life is the time measured for the plasma concentration to decrease by one half.
Time frame: 0 (pre-dose), 0.5, 1, 1.5, 2, 3.5, 4.5, 9.5, and 12.5 hr post-dose on Day 15 of Phase 1 Cycle 1
Maximum Observed Plasma Concentration (Cmax) of Gemcitabine
Time frame: 0 (pre-dose), 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 9 and 12 hr after start of infusion on Day 15 of Phase 1 Cycle 1
Area Under the Curve From Time Zero to Extrapolated Infinite Time [AUC (0 - ∞)] of Gemcitabine
AUC (0 - ∞) = Area under the plasma concentration versus time curve (AUC) from time zero (pre-dose) to extrapolated infinite time (0 - ∞). It is obtained from AUC (0 - t) plus AUC (t - ∞).
Time frame: 0 (pre-dose), 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 9 and 12 hr after start of infusion on Day 15 of Phase 1 Cycle 1
Plasma Decay Half-life (t1/2) of Gemcitabine
Plasma decay half-life is the time measured for the plasma concentration to decrease by one half.
Time frame: 0 (pre-dose), 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 9 and 12 hr after start of infusion on Day 15 of Phase 1 Cycle 1
Population Pharmacokinetics of Axitinib (AG-013736) in Phase 2
Data for this outcome measure are not reported here because the analysis population includes participants who were not enrolled in this study. ClinicalTrials.gov is designed for reporting results from only those participants who were enrolled in the study and described in the Participant Flow and Baseline Characteristics modules.
Time frame: Phase 2 Day 1 (Pre-dose), Day 29, Day 57 and then every 8 weeks until disease progression or discontinuation from study or up to 80 weeks
Percentage of Participants With Overall Response (OR)
Percentage of participants with OR based assessment of confirmed complete response (CR) or confirmed partial response (PR) according to Response Evaluation Criteria in Solid Tumors (RECIST). Confirmed responses are those that persist on repeat imaging study at least 4 weeks after initial documentation of response. CR are defined as the disappearance of all lesions (target and/or non-target). PR are those with at least 30% decrease in the sum of the longest dimensions of the target lesions taking as a reference the baseline sum of longest dimensions.
Time frame: Phase 2 baseline to disease progression or discontinuation from study, assessed every 8 weeks up to 80 weeks
Duration of Response (DR)
Time in days from the first documentation of objective tumor response to objective tumor progression or death due to any cancer. Duration of tumor response was calculated as the date of the first documentation of objective tumor progression or death due to cancer minus the date of the first CR or PR that was subsequently confirmed plus 1. DR was calculated for the subgroup of participants with a confirmed objective tumor response.
Time frame: Phase 2 baseline to disease progression or discontinuation from study due to any cause, assessed every 8 weeks up to 80 weeks
Progression-free Survival (PFS)
Time in days from randomization to first documentation of objective tumor progression or death due to any cause. PFS was calculated as first event date minus the date of randomization plus 1. Tumor progression was determined from oncologic assessment data (where data meet the criteria for progressive disease \[PD\]), or from adverse event (AE) data (where the outcome was "Death").
Time frame: Phase 2 baseline until the date of first documented progression or death due to any cause, assessed every 8 weeks up to 80 weeks
One Year Survival Probability
One year survival probability was defined as the probability of survival at one year after the date of randomization based on the Kaplan Meier estimate.
Time frame: Phase 2 baseline to disease progression or death due to any cause or at least 1 year after the first dose for the last participant
Change From Baseline in European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire (EORTC QLQ-C30) Score at Day 1 of Every Cycle and End of Study
EORTC QLQ-C30: included functional scales (physical, role, cognitive, emotional, and social), global health status, symptom scales (fatigue, pain, nausea/vomiting), and single items (dyspnoea, appetite loss, insomnia, constipation/diarrhea, and financial difficulties). Most questions used 4-point scale (1 'Not at All' to 4 'Very Much'); 2 questions used 7-point scale (1 'Very Poor' to 7 'Excellent'). Scores averaged, transformed to 0-100 scale; higher score=better level of functioning or greater degree of symptoms. Change from baseline=Cycle/Day score minus baseline score.
Time frame: Phase 2 baseline [Day (D)1 of Cycle (C)1], Day 1 of all subsequent cycles up to Cycle 14 and end of study (EoS).
Change From Baseline in 26-item Pancreatic Cancer-specific Quality of Life Questionnaire (QLQ-PAN26) Score at Day 1 of Every Cycle and End of Study
QLQ-PAN26 consists of 26 questions (Qs) relating to disease symptoms, treatment (Tx) side effects and emotional issues specific to pancreatic cancer (PC). Questions include on altered bowel habits, pain, dietary changes, disease and Tx-related symptoms and issues related to the emotional and social well-being of participants with PC. All 26 Qs are answered on 4-point Likert scale ranging from '1=not at all' to 4='very much' and subsequently transformed into scales that range from 0-100. Higher scores on functioning scales=better functioning; higher scores on the symptom scales=more symptoms.
Time frame: Phase 2 baseline [Day (D) 1 of Cycle (C)1], Day 1 of all subsequent cycles up to Cycle 14 and end of study (EoS).
| Milestone | Axitinib + Gemcitabine (Phase 1 Lead-In) | Axitinib + Gemcitabine | Gemcitabine |
|---|---|---|---|
| Started | 8 | 0 | 0 |
| Completed | 1 | 0 | 0 |
| Not completed | 7 | 0 | 0 |
| Withdrew: Lack of efficacy | 3 | 0 | 0 |
| Withdrew: Adverse event | 2 | 0 | 0 |
| Withdrew: Withdrawal by subject | 1 | 0 | 0 |
| Withdrew: Started chemotherapy at other institute | 1 | 0 | 0 |
| Milestone | Axitinib + Gemcitabine (Phase 1 Lead-In) | Axitinib + Gemcitabine | Gemcitabine |
|---|---|---|---|
| Started | 0 | 69 | 34 |
| Treated | 0 | 68 | 31 |
| Completed | 0 | 0 | 1 |
| Not completed | 0 | 69 | 33 |
| Withdrew: Lack of efficacy | 0 | 21 | 15 |
| Withdrew: Adverse event | 0 | 22 | 2 |
| Withdrew: Death | 0 | 8 | 2 |
| Withdrew: Other | 0 | 8 | 6 |
| Withdrew: Withdrawal by subject | 0 | 9 | 5 |
| Withdrew: Treatment not received | 0 | 1 | 3 |
Time in days from randomization to date of death due to any cause. OS was calculated as the death date minus the date of randomization plus 1. Death was determined from adverse event data (where outcome was death) or from follow-up contact data (where the participant current status was death).
| Days | Axitinib + Gemcitabine | Gemcitabine |
|---|---|---|
| Overall Survival (OS) | 210 (162 to 308) | 171 (125 to 267) |
Dose of axitinib (AG-013736) was confirmed if not more than 1 out of 6 participants experienced a DLT during first cycle. DLT included grade (Gr) 4 neutropenia or thrombocytopenia, greater than or equal to (\>=) Gr 3 anemia or non hematological toxicities for \>= 7 days (except alopecia) or \>= Gr 1 hemoptysis or \>=2 gram /24 hours proteinuria or inability to resume background chemotherapy or axitinib (AG-013736) dosing within 14 days of stopping due to treatment related toxicity.
| participants | Axitinib + Gemcitabine (Phase 1 Lead-In) |
|---|---|
| Dose Confirmation of Axitinib (AG-013736) on Basis of Number of Participants With Dose Limiting Toxicity (DLT) | 0 |
Dose of gemcitabine was confirmed if not more than 1 out of 6 participants experienced a DLT during first cycle. DLT included grade (Gr) 4 neutropenia or thrombocytopenia, greater than or equal to (\>=) Gr 3 anemia or non hematological toxicities for \>= 7 days (except alopecia) or \>= Gr 1 hemoptysis or \>=2 gram /24 hours proteinuria or inability to resume background chemotherapy or axitinib (AG-013736) dosing within 14 days of stopping due to treatment related toxicity.
| participants | Axitinib + Gemcitabine (Phase 1 Lead-In) |
|---|---|
| Dose Confirmation of Gemcitabine on Basis of Number of Participants With Dose Limiting Toxicity (DLT) | 0 |
| nanogram/milliliter (ng/mL) | Axitinib + Gemcitabine (Phase 1 Lead-In) |
|---|---|
| Maximum Observed Plasma Concentration (Cmax) for Axitinib (AG-013736) | 45.08 ± 34.32 |
AUC (0-24) = Area under the plasma concentration versus time curve (AUC) from time zero (pre-dose) to 24 hours (0-24).
| ng*hr/mL | Axitinib + Gemcitabine (Phase 1 Lead-In) |
|---|---|
| Area Under the Curve From Time Zero to 24 Hours [AUC (0-24)] of Axitinib (AG-013736) | 282.34 ± 135.27 |
Tmax was based on the actual time points when the samples were collected.
| hr | Axitinib + Gemcitabine (Phase 1 Lead-In) |
|---|---|
| Time to Reach Maximum Observed Plasma Concentration (Tmax) of Axitinib (AG-013736) | 1.52 (0.50 to 2.20) |
Plasma decay half-life is the time measured for the plasma concentration to decrease by one half.
| hr | Axitinib + Gemcitabine (Phase 1 Lead-In) |
|---|---|
| Plasma Decay Half-life (t1/2) of Axitinib (AG-013736) | 2.97 ± 1.95 |
| ng/mL | Axitinib + Gemcitabine (Phase 1 Lead-In) |
|---|---|
| Maximum Observed Plasma Concentration (Cmax) of Gemcitabine | 27280.0 ± 12599.1 |
AUC (0 - ∞) = Area under the plasma concentration versus time curve (AUC) from time zero (pre-dose) to extrapolated infinite time (0 - ∞). It is obtained from AUC (0 - t) plus AUC (t - ∞).
| ng*hr/mL | Axitinib + Gemcitabine (Phase 1 Lead-In) |
|---|---|
| Area Under the Curve From Time Zero to Extrapolated Infinite Time [AUC (0 - ∞)] of Gemcitabine | 13656.00 ± 4142.16 |
Plasma decay half-life is the time measured for the plasma concentration to decrease by one half.
| hr | Axitinib + Gemcitabine (Phase 1 Lead-In) |
|---|---|
| Plasma Decay Half-life (t1/2) of Gemcitabine | 0.310 ± 0.028 |
Data for this outcome measure are not reported here because the analysis population includes participants who were not enrolled in this study. ClinicalTrials.gov is designed for reporting results from only those participants who were enrolled in the study and described in the Participant Flow and Baseline Characteristics modules.
Results for this outcome have not been posted.
Percentage of participants with OR based assessment of confirmed complete response (CR) or confirmed partial response (PR) according to Response Evaluation Criteria in Solid Tumors (RECIST). Confirmed responses are those that persist on repeat imaging study at least 4 weeks after initial documentation of response. CR are defined as the disappearance of all lesions (target and/or non-target). PR are those with at least 30% decrease in the sum of the longest dimensions of the target lesions taking as a reference the baseline sum of longest dimensions.
| Percentage of Participants | Axitinib + Gemcitabine | Gemcitabine |
|---|---|---|
| Percentage of Participants With Overall Response (OR) | 7.2 (2.4 to 16.1) | 2.9 (0.1 to 15.3) |
Time in days from the first documentation of objective tumor response to objective tumor progression or death due to any cancer. Duration of tumor response was calculated as the date of the first documentation of objective tumor progression or death due to cancer minus the date of the first CR or PR that was subsequently confirmed plus 1. DR was calculated for the subgroup of participants with a confirmed objective tumor response.
| Days | Axitinib + Gemcitabine | Gemcitabine |
|---|---|---|
| Duration of Response (DR) | 379 (136 to 379) | 155 (NA to NA) |
Time in days from randomization to first documentation of objective tumor progression or death due to any cause. PFS was calculated as first event date minus the date of randomization plus 1. Tumor progression was determined from oncologic assessment data (where data meet the criteria for progressive disease \[PD\]), or from adverse event (AE) data (where the outcome was "Death").
| Days | Axitinib + Gemcitabine | Gemcitabine |
|---|---|---|
| Progression-free Survival (PFS) | 116 (109 to 160) | 113 (68 to 205) |
One year survival probability was defined as the probability of survival at one year after the date of randomization based on the Kaplan Meier estimate.
| Percent chance of survival | Axitinib + Gemcitabine | Gemcitabine |
|---|---|---|
| One Year Survival Probability | 36.81 (25.71 to 47.93) | 23.53 (11.48 to 38.01) |
EORTC QLQ-C30: included functional scales (physical, role, cognitive, emotional, and social), global health status, symptom scales (fatigue, pain, nausea/vomiting), and single items (dyspnoea, appetite loss, insomnia, constipation/diarrhea, and financial difficulties). Most questions used 4-point scale (1 'Not at All' to 4 'Very Much'); 2 questions used 7-point scale (1 'Very Poor' to 7 'Excellent'). Scores averaged, transformed to 0-100 scale; higher score=better level of functioning or greater degree of symptoms. Change from baseline=Cycle/Day score minus baseline score.
| units on a scale | Axitinib + Gemcitabine | Gemcitabine |
|---|---|---|
| Global QoL: Baseline | 55.60 ± 27.18 | 54.32 ± 21.10 |
| Physical Functioning: Baseline | 76.90 ± 24.73 | 82.22 ± 14.44 |
| Role Functioning: Baseline | 62.56 ± 33.21 | 60.26 ± 35.30 |
| Emotional Functioning: Baseline | 67.22 ± 26.17 | 66.98 ± 23.96 |
| Cognitive Functioning: Baseline | 82.82 ± 23.93 | 82.10 ± 19.57 |
| Social Functioning: Baseline | 67.44 ± 33.00 | 70.51 ± 29.56 |
| Fatigue: Baseline | 43.50 ± 29.78 | 42.80 ± 25.73 |
| Nausea and Vomiting: Baseline | 19.74 ± 28.24 | 13.58 ± 20.17 |
| Pain: Baseline | 40.00 ± 33.31 | 37.04 ± 31.80 |
| Dyspnea: Baseline | 12.50 ± 21.82 | 16.05 ± 26.75 |
| Insomnia: Baseline | 31.28 ± 31.66 | 39.51 ± 39.26 |
| Appetite loss: Baseline | 41.03 ± 40.30 | 33.33 ± 34.59 |
| Constipation: Baseline | 34.87 ± 37.93 | 38.27 ± 38.90 |
| Diarrhea: Baseline | 20.00 ± 27.51 | 16.05 ± 28.30 |
| Financial Difficulties: Baseline | 10.42 ± 19.59 | 28.40 ± 41.04 |
| Global QoL: Change at C2 D1 | -5.10 ± 21.17 | 3.33 ± 16.97 |
| Physical Functioning: Change at C2 D1 | -5.07 ± 18.85 | 0.95 ± 16.23 |
| Role Functioning: Change at C2 D1 | 0.33 ± 25.93 | 9.65 ± 29.56 |
| Emotional Functioning: Change at C2 D1 | 3.21 ± 21.34 | 7.94 ± 17.77 |
| Cognitive Functioning: Change at C2 D1 | -3.53 ± 21.48 | 1.59 ± 18.93 |
| Social Functioning: Change at C2 D1 | -4.17 ± 29.50 | -0.83 ± 28.85 |
| Fatigue: Change at C2 D1 | 1.42 ± 21.74 | -8.99 ± 26.67 |
| Nausea and Vomiting: Change at C2 D1 | -5.88 ± 26.84 | -1.59 ± 12.81 |
| Pain: Change at C2 D1 | -9.29 ± 27.89 | -16.67 ± 31.62 |
| Dyspnea: Change at C2 D1 | 9.33 ± 26.97 | -3.17 ± 25.61 |
| Insomnia: Change at C2 D1 | -9.15 ± 28.35 | -19.05 ± 34.27 |
| Appetite loss: Change at C2 D1 | -0.65 ± 35.58 | -14.29 ± 35.86 |
| Constipation: Change at C2 D1 | -9.62 ± 32.56 | -14.29 ± 29.00 |
| Diarrhea: Change at C2 D1 | -1.28 ± 29.49 | 0.00 ± 18.26 |
| Financial Difficulties: Change at C2 D1 | 0.67 ± 19.62 | -4.76 ± 19.11 |
| Global QoL: Change at C3 D1 | -9.17 ± 30.36 | 6.67 ± 15.17 |
| Physical Functioning: Change at C3 D1 | -8.13 ± 21.46 | 3.44 ± 18.73 |
| Role Functioning: Change at C3 D1 | -5.56 ± 27.71 | 13.10 ± 25.47 |
| Emotional Functioning: Change at C3 D1 | -1.69 ± 26.80 | 12.22 ± 19.89 |
| Cognitive Functioning: Change at C3 D1 | -4.88 ± 24.79 | 2.22 ± 16.51 |
| Social Functioning: Change at C3 D1 | -4.07 ± 32.66 | 5.56 ± 24.93 |
| Fatigue: Change at C3 D1 | 7.41 ± 28.61 | -8.73 ± 26.57 |
| Nausea and Vomiting: Change at C3 D1 | -4.37 ± 29.00 | -2.56 ± 16.45 |
| Pain: Change at C3 D1 | -6.75 ± 33.75 | -23.33 ± 30.08 |
| Dyspnea: Change at C3 D1 | 3.25 ± 27.69 | -7.14 ± 19.30 |
| Insomnia: Change at C3 D1 | -10.32 ± 34.13 | -11.90 ± 38.36 |
| Appetite loss: Change at C3 D1 | 11.11 ± 39.42 | -5.13 ± 29.96 |
| Constipation: Change at C3 D1 | -10.57 ± 32.86 | -13.33 ± 35.19 |
| Diarrhea: Change at C3 D1 | 7.32 ± 32.07 | 4.44 ± 30.52 |
| Financial Difficulties: Change at C3 D1 | 3.33 ± 24.81 | -2.22 ± 26.63 |
| Global QoL: Change at C4 D1 | -6.67 ± 21.04 | -1.03 ± 15.27 |
| Physical Functioning: Change at C4 D1 | -6.67 ± 23.15 | -1.03 ± 15.36 |
| Role Functioning: Change at C4 D1 | -7.81 ± 29.63 | 9.72 ± 36.56 |
| Emotional Functioning: Change at C4 D1 | -3.23 ± 22.64 | 9.03 ± 36.56 |
| Cognitive Functioning: Change at C4 D1 | -6.99 ± 25.74 | 0.00 ± 15.89 |
| Social Functioning: Change at C4 D1 | -8.60 ± 35.45 | -1.52 ± 24.10 |
| Fatigue: Change at C4 D1 | 7.47 ± 25.19 | -3.42 ± 25.41 |
| Nausea and Vomiting: Change at C4 D1 | -4.69 ± 19.96 | 6.41 ± 18.68 |
| Pain: Change at C4 D1 | -16.67 ± 29.02 | -11.54 ± 28.37 |
| Dyspnea: Change at C4 D1 | 0.00 ± 28.54 | -5.13 ± 29.96 |
| Insomnia: Change at C4 D1 | -11.46 ± 28.85 | -5.13 ± 32.90 |
| Appetite loss: Change at C4 D1 | 6.25 ± 36.35 | -2.78 ± 33.21 |
| Constipation: Change at C4 D1 | -24.44 ± 37.07 | -25.00 ± 40.51 |
| Diarrhea: Change at C4 D1 | 7.53 ± 39.17 | 5.56 ± 34.33 |
| Financial Difficulties: Change at C4 D1 | 1.15 ± 22.68 | -8.33 ± 20.72 |
| Global QoL: Change at C5 D1 | -9.29 ± 27.82 | 10.71 ± 21.36 |
| Physical Functioning: Change at C5 D1 | -8.57 ± 23.08 | 0.00 ± 22.25 |
| Role Functioning: Change at C5 D1 | -8.93 ± 29.22 | 7.14 ± 28.64 |
| Emotional Functioning: Change at C5 D1 | -3.87 ± 22.96 | 20.24 ± 14.32 |
| Cognitive Functioning: Change at C5 D1 | -2.38 ± 24.73 | 7.14 ± 16.27 |
| Social Functioning: Change at C5 D1 | -15.48 ± 33.92 | 4.76 ± 23.00 |
| Fatigue: Change at C5 D1 | 9.72 ± 28.59 | -15.28 ± 17.76 |
| Nausea and Vomiting: Change at C5 D1 | 0.00 ± 26.06 | -6.25 ± 15.27 |
| Pain: Change at C5 D1 | -5.36 ± 34.26 | -25.00 ± 26.73 |
| Dyspnea: Change at C5 D1 | 9.52 ± 27.00 | -12.50 ± 24.80 |
| Insomnia: Change at C5 D1 | -19.05 ± 35.63 | -29.17 ± 33.03 |
| Appetite loss: Change at C5 D1 | 0.00 ± 42.55 | -20.83 ± 43.42 |
| Constipation: Change at C5 D1 | -21.43 ± 35.39 | -33.33 ± 38.49 |
| Diarrhea: Change at C5 D1 | 7.14 ± 33.16 | -4.76 ± 29.99 |
| Financial Difficulties: Change at C5 D1 | 0.00 ± 22.65 | 0.00 ± 36.51 |
| Global QoL: Change at C6 D1 | -14.22 ± 20.36 | -5.56 ± 12.73 |
| Physical Functioning: Change at C6 D1 | -6.32 ± 25.38 | 6.67 ± 18.86 |
| Role Functioning: Change at C6 D1 | -9.65 ± 27.95 | 16.67 ± 47.14 |
| Emotional Functioning: Change at C6 D1 | 2.19 ± 15.92 | 8.33 ± 14.43 |
| Cognitive Functioning: Change at C6 D1 | -0.88 ± 18.82 | 11.11 ± 9.62 |
| Social Functioning: Change at C6 D1 | -2.63 ± 27.92 | -16.67 ± 16.67 |
| Fatigue: Change at C6 D1 | 6.73 ± 24.19 | -16.67 ± 39.28 |
| Nausea and Vomiting: Change at C6 D1 | -4.39 ± 22.80 | -8.33 ± 11.79 |
| Pain: Change at C6 D1 | -8.77 ± 30.11 | -33.33 ± 16.67 |
| Dyspnea: Change at C6 D1(n=18,2) | -1.85 ± 21.30 | 0.00 ± 47.14 |
| Insomnia: Change at C6 D1 | -7.02 ± 30.59 | -16.67 ± 23.57 |
| Appetite loss: Change at C6 D1(n=19,2) | -3.51 ± 53.16 | -16.67 ± 70.71 |
| Constipation: Change at C6 D1 | -10.53 ± 35.23 | -33.33 ± 33.33 |
| Diarrhea: Change at C6 D1 | -1.75 ± 28.27 | 0.00 ± 33.33 |
| Financial Difficulties: Change at C6 D1 | 1.75 ± 13.49 | -22.22 ± 38.49 |
| Global QoL: Change at C7 D1 | -4.63 ± 37.76 | -16.67 ± 14.43 |
| Physical Functioning: Change at C7 D1 | -3.33 ± 24.80 | -22.22 ± 36.72 |
| Role Functioning: Change at C7 D1 | -15.00 ± 30.88 | 33.33 ± 70.71 |
| Emotional Functioning: Change at C7 D1 | -8.33 ± 13.03 | -7.41 ± 21.58 |
| Cognitive Functioning: Change at C7 D1 | 1.67 ± 24.15 | -5.56 ± 9.62 |
| Social Functioning: Change at C7 D1 | -15.00 ± 41.16 | -25.00 ± 11.79 |
| Fatigue: Change at C7 D1 | -2.22 ± 25.01 | 14.81 ± 42.07 |
| Nausea and Vomiting: Change at C7D1 | 1.67 ± 21.44 | 16.67 ± 0.00 |
| Pain: Change at C7 D1 | -3.33 ± 32.20 | -11.11 ± 41.94 |
| Dyspnea: Change at C7 D1 | 16.67 ± 23.57 | 33.33 ± 33.33 |
| Insomnia: Change at C7 D1 | -10.00 ± 35.31 | 11.11 ± 38.49 |
| Appetite loss: Change at C7 D1 | -10.00 ± 58.90 | 22.22 ± 50.92 |
| Constipation: Change at C7 D1 | -13.33 ± 47.66 | -66.67 ± 57.74 |
| Diarrhea: Change at C7 D1 | 3.33 ± 29.19 | 0.00 ± 0.00 |
| Financial Difficulties: Change at C7 D1 | -6.67 ± 21.08 | 0.00 ± 0.00 |
| Global QoL: Change at C8 D1 | -12.50 ± 33.62 | -33.33 ± NA |
| Physical Functioning Change at C8 D1 | -10.67 ± 22.71 | -20.00 ± NA |
| Role Functioning: Change at C8 D1 | -13.33 ± 23.31 | -33.33 ± NA |
| Emotional Functioning: Change at C8 D1 | -7.50 ± 18.61 | 0.00 ± NA |
| Cognitive Functioning: Change at C8 D1 | 0.00 ± 22.22 | -16.67 ± NA |
| Social Functioning: Change at C8 D1 | -11.67 ± 34.29 | -16.67 ± NA |
| Fatigue: Change at C8 D1 | 4.44 ± 25.23 | 2.22 ± NA |
| Nausea and Vomiting: Change at C8 D1 | 0.00 ± 19.25 | 16.67 ± NA |
| Pain: Change at C8 D1 | -8.33 ± 37.06 | -16.67 ± NA |
| Dyspnea: Change at C8 D1 | 14.81 ± 29.40 | 33.33 ± NA |
| Insomnia: Change at C8 D1 | -20.00 ± 47.66 | 0.00 ± NA |
| Appetite loss: Change at C8 D1 | -3.33 ± 48.30 | 33.33 ± NA |
| Constipation: Change at C8 D1 | -3.33 ± 29.19 | 0.00 ± NA |
| Diarrhea: Change at C8 D1 | 6.67 ± 37.84 | -66.67 ± NA |
| Financial Difficulties: Change at C8 D1 | -3.33 ± 18.92 | 0.00 ± NA |
| Global QoL: Change at C9 D1 | -17.71 ± 36.03 | -33.33 ± NA |
| Physical Functioning: Change at C9 D1 | -6.67 ± 20.16 | -40.00 ± NA |
| Role Functioning: Change at C9 D1 | -29.17 ± 24.80 | -33.33 ± NA |
| Emotional Functioning: Change at C9 D1 | -3.13 ± 13.32 | -8.33 ± NA |
| Cognitive Functioning: Change at C9 D1 | -2.08 ± 28.78 | -33.33 ± NA |
| Social Functioning: Change at C9 D1 | -6.25 ± 47.09 | -33.33 ± NA |
| Fatigue: Change at C9 D1 | 18.06 ± 33.56 | 33.33 ± NA |
| Nausea and Vomiting: Change at C9 D1 | -8.33 ± 17.82 | 16.67 ± NA |
| Pain: Change at C9 D1 | 0.00 ± 30.86 | 0.00 ± NA |
| Dyspnea: Change at C9 D1 | 19.05 ± 26.23 | 33.33 ± NA |
| Insomnia: Change at C9 D1 | -4.17 ± 33.03 | 0.00 ± NA |
| Appetite loss: Change at C9 D1 | 8.33 ± 63.62 | 33.33 ± NA |
| Constipation: Change at C9 D1 | -8.33 ± 38.83 | 0.00 ± NA |
| Diarrhea: Change at C9 D1 | 12.50 ± 43.42 | -66.67 ± NA |
| Financial Difficulties: Change at C9 D1 | -4.17 ± 21.36 | 0.00 ± NA |
| Global QoL: Change at C10 D1 | -16.67 ± 21.52 | -33.33 ± NA |
| Physical Functioning: Change at C10 D1 | -19.05 ± 13.01 | -46.67 ± NA |
| Role Functioning: Change at C10 D1 | -23.81 ± 21.21 | -50.00 ± NA |
| Emotional Functioning: Change at C10 D1 | -20.24 ± 23.00 | -16.67 ± NA |
| Cognitive Functioning: Change at C10 D1 | -9.52 ± 21.21 | -33.33 ± NA |
| Social Functioning: Change at C10 D1 | -21.43 ± 31.50 | -50.00 ± NA |
| Fatigue: Change at C10 D1 | 25.40 ± 24.61 | 55.56 ± NA |
| Nausea and Vomiting: Change at C10 D1 | 0.00 ± 25.46 | 16.67 ± NA |
| Pain: Change at C10 D1 | 11.90 ± 35.63 | 16.67 ± NA |
| Dyspnea: Change at C10 D1 | 22.22 ± 27.22 | 33.33 ± NA |
| Insomnia: Change at C10 D1 | 4.76 ± 23.00 | 0.00 ± NA |
| Appetite loss: Change at C10 D1 | 23.81 ± 46.00 | 33.33 ± NA |
| Constipation: Change at C10 D1 | -19.05 ± 37.80 | 0.00 ± NA |
| Diarrhea: Change at C10 D1 | 9.52 ± 31.71 | -66.67 ± NA |
| Financial Difficulties: Change at C10 D1 | -4.76 ± 23.00 | 0.00 ± NA |
| Global QoL: Change at C11 D1 | -38.89 ± 53.58 | -33.33 ± NA |
| Physical Functioning: Change at C11 D1 | -24.44 ± 36.72 | -40.00 ± NA |
| Role Functioning: Change at C11 D1 | -38.89 ± 53.58 | -66.67 ± NA |
| Emotional Functioning: Change at C11 D1 | -25.00 ± 52.04 | -8.33 ± NA |
| Cognitive Functioning: Change at C11 D1 | -27.78 ± 63.10 | -33.33 ± NA |
| Social Functioning: Change at C11 D1 | -38.89 ± 53.58 | -66.67 ± NA |
| Fatigue: Change at C11 D1 | 37.04 ± 46.26 | 22.22 ± NA |
| Nausea and Vomiting: Change at C11 D1 | 27.78 ± 63.10 | 16.67 ± NA |
| Pain: Change at C11 D1 | 22.22 ± 69.39 | -16.67 ± NA |
| Dyspnea: Change at C11 D1 | 22.22 ± 69.39 | 33.33 ± NA |
| Insomnia: Change at C11 D1 | 22.22 ± 69.39 | 0.00 ± NA |
| Appetite loss: Change at C11 D1 | 44.44 ± 50.92 | 0.00 ± NA |
| Constipation: Change at C11 D1 | 0.00 ± 33.33 | 0.00 ± NA |
| Diarrhea: Change at C11 D1 | 11.11 ± 19.25 | -66.67 ± NA |
| Financial Difficulties: Change at C11 D1 | -11.11 ± 19.25 | 0.00 ± NA |
| Global QoL: Change at C12 D1 | -11.11 ± 17.35 | — |
| Physical Functioning: Change at C12 D1 | -6.67 ± 6.67 | — |
| Role Functioning: Change at C12 D1 | -11.11 ± 19.25 | — |
| Emotional Functioning: Change at C12 D1 | -2.78 ± 20.97 | — |
| Cognitive Functioning: Change at C12 D1 | 0.00 ± 16.67 | — |
| Social Functioning: Change at C12 D1 | -5.56 ± 9.62 | — |
| Fatigue: Change at C12 D1 | 7.41 ± 12.83 | — |
| Nausea and Vomiting: Change at C12 D1 | 16.67 ± 60.09 | — |
| Pain: Change at C12 D1 | -5.56 ± 9.62 | — |
| Dyspnea: Change at C12 D1 | 0.00 ± 0.00 | — |
| Insomnia: Change at C12 D1 | -11.11 ± 19.25 | — |
| Appetite loss: Change at C12 D1 | 22.22 ± 19.25 | — |
| Constipation: Change at C12 D1 | -22.22 ± 38.49 | — |
| Diarrhea: Change at C12 D1 | 22.22 ± 19.25 | — |
| Financial Difficulties: Change at C12 D1 | -11.11 ± 19.25 | — |
| Global QoL: Change at C13 D1 | -50.00 ± 35.36 | — |
| Physical Functioning: Change at C13 D1 | -23.33 ± 33.00 | — |
| Role Functioning: Change at C13 D1 | -41.67 ± 35.36 | — |
| Emotional Functioning: Change at C13 D1 | -8.33 ± 11.79 | — |
| Cognitive Functioning: Change at C13 D1 | 0.00 ± 0.00 | — |
| Social Functioning: Change at C13 D1 | -8.33 ± 35.36 | — |
| Fatigue: Change at C13 D1 | 33.33 ± 47.14 | — |
| Nausea and Vomiting: Change at C13 D1 | -8.33 ± 35.36 | — |
| Pain: Change at C13 D1 | 41.67 ± 58.93 | — |
| Dyspnea: Change at C13 D1 | 0.00 ± NA | — |
| Insomnia: Change at C13 D1 | 0.00 ± 0.00 | — |
| Appetite loss: Change at C13 D1 | 33.33 ± 47.14 | — |
| Constipation: Change at C13 D1 | -16.67 ± 23.57 | — |
| Diarrhea: Change at C13 D1 | 16.67 ± 23.57 | — |
| Financial Difficulties: Change at C13 D1 | -16.67 ± 23.57 | — |
| Global QoL: Change at C14 D1 | -16.67 ± NA | — |
| Physical Functioning: Change at C14 D1 | -6.67 ± NA | — |
| Role Functioning: Change at C14 D1 | -33.33 ± NA | — |
| Emotional Functioning: Change at C14 D1 | -8.33 ± NA | — |
| Cognitive Functioning: Change at C14 D1 | 16.67 ± NA | — |
| Social Functioning: Change at C14 D1 | 0.00 ± NA | — |
| Fatigue: Change at C14 D1 | 22.22 ± NA | — |
| Nausea and Vomiting: Change at C14 D1 | 0.00 ± NA | — |
| Pain: Change at C14 D1 | 16.67 ± NA | — |
| Dyspnea: Change at C14 D1 | 33.33 ± NA | — |
| Insomnia: Change at C14 D1 | -33.33 ± NA | — |
| Appetite loss: Change at C14 D1 | 0.00 ± NA | — |
| Constipation: Change at C14 D1 | 0.00 ± NA | — |
| Diarrhea: Change at C14 D1 | 33.33 ± NA | — |
| Financial Difficulties: Change at C14 D1 | -33.33 ± NA | — |
| Global QoL: Change at EoS | -54.17 ± 29.46 | 0.00 ± NA |
| Physical Functioning: Change at EoS | -70.00 ± 4.71 | 0.00 ± NA |
| Role Functioning: Change at EoS | -33.33 ± 23.57 | 0.00 ± NA |
| Emotional Functioning: Change at EoS | -66.67 ± 35.36 | -25.00 ± NA |
| Cognitive Functioning: Change at EoS | -66.67 ± 0.00 | 0.00 ± NA |
| Social Functioning: Change at EoS | -83.33 ± 23.57 | 0.00 ± NA |
| Fatigue: Change at EoS | 55.56 ± 15.71 | -11.11 ± NA |
| Nausea and Vomiting: Change at EoS | 33.33 ± 23.57 | 0.00 ± NA |
| Pain: Change at EoS | 41.67 ± 82.50 | 16.67 ± NA |
| Dyspnea: Change at EoS | 83.33 ± 23.57 | 0.00 ± NA |
| Insomnia: Change at EoS | 66.67 ± 47.14 | 33.33 ± NA |
| Appetite loss: Change at EoS | 50.00 ± 70.71 | 0.00 ± NA |
| Constipation: Change at EoS | -16.67 ± 117.85 | 0.00 ± NA |
| Diarrhea: Change at EoS | 33.33 ± 47.14 | 0.00 ± NA |
| Financial Difficulties: Change at EoS | -16.67 ± 23.57 | 0.00 ± NA |
QLQ-PAN26 consists of 26 questions (Qs) relating to disease symptoms, treatment (Tx) side effects and emotional issues specific to pancreatic cancer (PC). Questions include on altered bowel habits, pain, dietary changes, disease and Tx-related symptoms and issues related to the emotional and social well-being of participants with PC. All 26 Qs are answered on 4-point Likert scale ranging from '1=not at all' to 4='very much' and subsequently transformed into scales that range from 0-100. Higher scores on functioning scales=better functioning; higher scores on the symptom scales=more symptoms.
| units on a scale | Axitinib + Gemcitabine | Gemcitabine |
|---|---|---|
| Pancreatic Pain: Baseline | 37.52 ± 27.88 | 38.89 ± 21.18 |
| Eating Related Items: Baseline | 40.40 ± 35.18 | 33.95 ± 27.92 |
| Altered Bowel Habits: Baseline | 22.32 ± 26.19 | 25.31 ± 28.26 |
| Jaundice: Baseline | 9.89 ± 18.34 | 15.38 ± 23.06 |
| Body Image: Baseline | 31.64 ± 29.80 | 26.54 ± 25.84 |
| Health Care Satisfaction: Baseline | 79.38 ± 27.57 | 69.75 ± 25.33 |
| Sexual Functioning: Baseline | 44.35 ± 34.42 | 57.97 ± 37.56 |
| Ascites: Baseline | 37.29 ± 31.00 | 25.93 ± 25.04 |
| Indigestion: Baseline | 24.86 ± 28.09 | 30.86 ± 34.50 |
| Flatulence: Baseline | 35.59 ± 32.67 | 39.51 ± 29.29 |
| Cachexia: Baseline | 33.62 ± 25.43 | 31.48 ± 23.72 |
| Side Effects: Baseline | 27.78 ± 24.80 | 27.35 ± 21.77 |
| Fear of Future Health: Baseline | 63.22 ± 31.03 | 59.26 ± 33.76 |
| Ability to Plan Future: Baseline | 39.55 ± 35.27 | 41.98 ± 36.51 |
| Pancreatic Pain: Change at C2 D1 | -11.05 ± 25.39 | -13.64 ± 22.05 |
| Eating Related Items: Change at C2 D1 | -0.38 ± 34.19 | -3.79 ± 27.67 |
| Altered Bowel Habits: Change at C2 D1 | 8.33 ± 28.19 | -11.36 ± 22.05 |
| Jaundice: Change at C2 D1 | 0.00 ± 20.65 | -12.70 ± 25.22 |
| Body Image: Change at C2 D1 | 7.95 ± 26.53 | -7.14 ± 25.04 |
| Health Care Satisfaction: Change at C2 D1 | 0.39 ± 34.60 | -3.97 ± 37.60 |
| Sexual Functioning: Change at C2 D1 | -2.56 ± 22.14 | 18.63 ± 38.59 |
| Ascites: Change at C2 D1 | -10.85 ± 36.89 | -3.03 ± 22.79 |
| Indigestion: Change at C2 D1 | -4.65 ± 24.75 | -10.61 ± 37.64 |
| Flatulence: Change at C2 D1 | 5.30 ± 34.43 | -9.09 ± 21.04 |
| Cachexia: Change at C2 D1 | 9.47 ± 19.15 | -3.03 ± 17.55 |
| Side Effects: Change at C2 D1 | 7.70 ± 16.39 | -3.17 ± 20.90 |
| Fear of Future Health: Change at C2 D1 | -2.33 ± 23.45 | 0.00 ± 31.62 |
| Ability to Plan Future: Change at C2 D1 | 4.55 ± 35.65 | -1.67 ± 27.52 |
| Pancreatic Pain: Change at C3 D1 | -8.92 ± 24.62 | -23.78 ± 20.61 |
| Eating Related Items: Change at C3 D1 | 3.07 ± 37.34 | -10.42 ± 28.46 |
| Altered Bowel Habits: Change at C3 D1 | 10.53 ± 31.34 | -8.33 ± 31.03 |
| Jaundice: Change at C3 D1 | 2.19 ± 13.52 | -9.38 ± 26.51 |
| Body Image: Change at C3 D1 | 13.51 ± 30.89 | -5.21 ± 29.01 |
| Health Care Satisfaction: Change at C3 D1 | -5.41 ± 40.07 | 5.21 ± 24.88 |
| Sexual Functioning: Change at C3 D1 | -3.13 ± 21.77 | -4.44 ± 31.79 |
| Ascites: Change at C3 D1 | -2.63 ± 28.35 | -4.17 ± 23.96 |
| Indigestion: Change at C3 D1 | -4.50 ± 34.39 | -15.56 ± 37.52 |
| Flatulence: Change at C3 D1 | 9.65 ± 37.09 | 6.25 ± 27.81 |
| Cachexia: Change at C3 D1 | 14.47 ± 24.56 | 5.21 ± 17.97 |
| Side Effects: Change at C3 D1 | 11.55 ± 27.41 | -7.64 ± 26.28 |
| Fear of Future Health: Change at C3 D1 | -2.86 ± 34.65 | -2.22 ± 42.66 |
| Ability to Plan Future: Change at C3 D1 | 9.01 ± 43.50 | -12.50 ± 34.16 |
| Pancreatic Pain: Change at C4 D1 | -18.30 ± 26.90 | -14.10 ± 22.92 |
| Eating Related Items: Change at C4 D1 | -7.47 ± 26.57 | 5.13 ± 36.88 |
| Altered Bowel Habits: Change at C4 D1 | 16.09 ± 35.21 | 3.85 ± 28.99 |
| Jaundice: Change at C4 D1 | 1.72 ± 19.59 | -11.11 ± 16.41 |
| Body Image: Change at C4 D1 | 12.82 ± 31.02 | 8.97 ± 26.01 |
| Health Care Satisfaction: Change at C4 D1 | -1.92 ± 49.51 | -8.97 ± 29.36 |
| Sexual Functioning: Change at C4 D1 | -5.30 ± 27.88 | -2.78 ± 40.72 |
| Ascites: Change at C4 D1 | -6.90 ± 25.79 | 2.56 ± 28.74 |
| Indigestion: Change at C4 D1 | -9.52 ± 33.77 | -2.56 ± 37.17 |
| Flatulence: Change at C4 D1 | 1.15 ± 39.32 | -2.56 ± 25.32 |
| Cachexia: Change at C4 D1 | 9.20 ± 29.07 | -3.85 ± 24.68 |
| Side Effects: Change at C4 D1 | 11.88 ± 28.59 | -3.24 ± 19.88 |
| Fear of Future Health: Change at C4 D1 | -2.78 ± 41.61 | 5.13 ± 38.12 |
| Ability to Plan Future: Change at C4 D1 | 10.26 ± 53.97 | -5.13 ± 46.84 |
| Pancreatic Pain: Change at C5 D1 | -7.26 ± 27.99 | -18.52 ± 24.22 |
| Eating Related Items: Change at C5 D1 | 0.00 ± 45.22 | -7.41 ± 26.50 |
| Altered Bowel Habits: Change at C5 D1 | 13.46 ± 30.92 | -14.81 ± 29.40 |
| Jaundice: Change at C5 D1 | 3.85 ± 19.04 | -20.37 ± 36.11 |
| Body Image: Change at C5 D1 | 14.00 ± 28.74 | -11.11 ± 39.97 |
| Health Care Satisfaction: Change at C5 D1 | -2.67 ± 51.52 | 7.41 ± 34.47 |
| Sexual Functioning: Change at C5 D1 | -1.75 ± 20.71 | 1.85 ± 24.22 |
| Ascites: Change at C5 D1 | -5.13 ± 24.39 | -11.11 ± 40.82 |
| Indigestion: Change at C5 D1 | -3.85 ± 28.79 | -25.93 ± 49.38 |
| Flatulence: Change at C5 D1 | -1.33 ± 28.02 | -11.11 ± 40.82 |
| Cachexia: Change at C5 D1 | 10.26 ± 36.84 | -5.56 ± 18.63 |
| Side Effects: Change at C5 D1 | 10.04 ± 28.55 | -11.73 ± 17.22 |
| Fear of Future Health: Change at C5 D1 | 0.00 ± 35.44 | 14.81 ± 29.40 |
| Ability to Plan Future: Change at C5 D1 | 20.00 ± 41.94 | -11.11 ± 16.67 |
| Pancreatic Pain: Change at C6 D1 | -3.76 ± 24.06 | -12.50 ± 30.81 |
| Eating Related Items: Change at C6 D1 | -4.90 ± 50.95 | 8.33 ± 21.52 |
| Altered Bowel Habits: Change at C6 D1 | 13.73 ± 25.16 | -8.33 ± 28.87 |
| Jaundice: Change at C6 D1 | 1.96 ± 11.61 | -16.67 ± 45.13 |
| Body Image: Change at C6 D1 | 23.96 ± 31.60 | 0.00 ± 0.00 |
| Health Care Satisfaction: Change at C6 D1 | -11.46 ± 42.04 | -25.00 ± 21.52 |
| Sexual Functioning: Change at C6 D1 | -7.69 ± 30.14 | -20.83 ± 49.77 |
| Ascites: Change at C6 D1 | -1.96 ± 24.92 | -8.33 ± 31.91 |
| Indigestion: Change at C6 D1 | 3.92 ± 35.12 | -16.67 ± 19.25 |
| Flatulence: Change at C6 D1 | 1.96 ± 27.56 | -8.33 ± 16.67 |
| Cachexia: Change at C6 D1 | 4.90 ± 31.05 | -20.83 ± 15.96 |
| Side Effects: Change at C6 D1 | 16.34 ± 30.40 | -22.22 ± 15.71 |
| Fear of Future Health: Change at C6 D1 | -4.44 ± 45.19 | 0.00 ± 0.00 |
| Ability to Plan Future: Change at C6 D1 | 12.50 ± 54.26 | 16.67 ± 63.83 |
| Pancreatic Pain: Change at C7 D1 | -3.70 ± 22.09 | -16.67 ± 11.79 |
| Eating Related Items: Change at C7 D1 | -14.81 ± 31.67 | 8.33 ± 11.79 |
| Altered Bowel Habits: Change at C7 D1 | 5.56 ± 23.57 | 25.00 ± 58.93 |
| Jaundice: Change at C7 D1 | 5.56 ± 11.79 | -41.67 ± 58.93 |
| Body Image: Change at C7 D1 | 16.67 ± 41.67 | -25.00 ± 58.93 |
| Health Care Satisfaction: Change at C7 D1 | 5.56 ± 26.35 | -33.33 ± 0.00 |
| Sexual Functioning: Change at C7 D1 | -9.52 ± 18.90 | -41.67 ± 11.79 |
| Ascites: Change at C7 D1 | 0.00 ± 0.00 | 0.00 ± 0.00 |
| Indigestion: Change at C7 D1 | -7.41 ± 22.22 | 0.00 ± 0.00 |
| Flatulence: Change at C7 D1 | -3.70 ± 30.93 | -16.67 ± 23.57 |
| Cachexia: Change at C7 D1 | 5.56 ± 25.00 | -8.33 ± 35.36 |
| Side Effects: Change at C7 D1 | 8.64 ± 25.93 | -22.22 ± 31.43 |
| Fear of Future Health: Change at C7 D1 | 4.17 ± 27.82 | -16.67 ± 70.71 |
| Ability to Plan Future: Change at C7 D1 | 14.81 ± 55.56 | 33.33 ± 47.14 |
| Pancreatic Pain: Change at C8 D1 | -1.54 ± 25.99 | -25.00 ± NA |
| Eating Related Items: Change at C8 D1 | 3.70 ± 48.43 | 16.67 ± NA |
| Altered Bowel Habits: Change at C8 D1 | 14.81 ± 22.74 | -33.33 ± NA |
| Jaundice: Change at C8 D1 | 9.26 ± 12.11 | -83.33 ± NA |
| Body Image: Change at C8 D1 | 22.22 ± 37.27 | 16.67 ± NA |
| Health Care Satisfaction: Change at C8 D1 | 3.70 ± 27.36 | -33.33 ± NA |
| Sexual Functioning: Change at C8 D1 | -7.14 ± 13.11 | 0.00 ± NA |
| Ascites: Change at C8 D1 | -3.70 ± 26.06 | 0.00 ± NA |
| Indigestion: Change at C8 D1 | -7.41 ± 40.06 | 0.00 ± NA |
| Flatulence: Change at C8 D1 | -11.11 ± 33.33 | -33.33 ± NA |
| Cachexia: Change at C8 D1 | 11.11 ± 26.35 | -16.67 ± NA |
| Side Effects: Change at C8 D1 | 11.11 ± 35.14 | 0.00 ± NA |
| Fear of Future Health: Change at C8 D1 | 4.17 ± 45.21 | 33.33 ± NA |
| Ability to Plan Future: Change at C8 D1 | 11.11 ± 64.55 | 66.67 ± NA |
| Pancreatic Pain: Change at C9 D1 | 0.00 ± 30.43 | -16.67 ± NA |
| Eating Related Items: Change at C9 D1 | 14.29 ± 39.00 | 0.00 ± NA |
| Altered Bowel Habits: Change at C9 D1 | 23.81 ± 25.20 | -50.00 ± NA |
| Jaundice: Change at C9 D1 | 9.52 ± 16.27 | -66.67 ± NA |
| Body Image: Change at C9 D1 | 28.57 ± 35.63 | 0.00 ± NA |
| Health Care Satisfaction: Change at C9 D1 | 2.38 ± 24.40 | -33.33 ± NA |
| Sexual Functioning: Change at C9 D1 | -13.33 ± 29.81 | 0.00 ± NA |
| Ascites: Change at C9 D1 | -11.11 ± 34.43 | 33.33 ± NA |
| Indigestion: Change at C9 D1 | 4.76 ± 35.63 | 0.00 ± NA |
| Flatulence: Change at C9 D1 | 14.29 ± 26.23 | 0.00 ± NA |
| Cachexia: Change at C9 D1 | 23.81 ± 34.50 | 0.00 ± NA |
| Side Effects: Change at C9 D1 | 31.75 ± 33.60 | 0.00 ± NA |
| Fear of Future Health: Change at C9 D1 | -16.67 ± 40.82 | 33.33 ± NA |
| Ability to Plan Future: Change at C9 D1 | 19.05 ± 42.41 | 33.33 ± NA |
| Pancreatic Pain: Change at C10 D1 | 8.33 ± 25.28 | -16.67 ± NA |
| Eating Related Items: Change at C10 D1 | 25.00 ± 25.28 | 0.00 ± NA |
| Altered Bowel Habits: Change at C10 D1 | 27.78 ± 22.77 | -50.00 ± NA |
| Jaundice: Change at C10 D1 | 2.78 ± 16.39 | -83.33 ± NA |
| Body Image: Change at C10 D1 | 25.00 ± 29.34 | 0.00 ± NA |
| Health Care Satisfaction: Change at C10 D1 | 13.89 ± 30.58 | -33.33 ± NA |
| Sexual Functioning: Change at C10 D1 | -13.33 ± 29.81 | -33.33 ± NA |
| Ascites: Change at C10 D1 | 0.00 ± 21.08 | 33.33 ± NA |
| Indigestion: Change at C10 D1 | 27.78 ± 25.09 | 0.00 ± NA |
| Flatulence: Change at C10 D1 | 16.67 ± 18.26 | 0.00 ± NA |
| Cachexia: Change at C10 D1 | 25.00 ± 39.09 | 16.67 ± NA |
| Side Effects: Change at C10 D1 | 37.04 ± 28.69 | 11.11 ± NA |
| Fear of Future Health: Change at C10 D1 | 0.00 ± 0.00 | 33.33 ± NA |
| Ability to Plan Future: Change at C10 D1 | 33.33 ± 42.16 | 33.33 ± NA |
| Pancreatic Pain: Change at C11 D1 | 5.56 ± 47.39 | -8.33 ± NA |
| Eating Related Items: Change at C11 D1 | 38.89 ± 53.58 | 33.33 ± NA |
| Altered Bowel Habits: Change at C11 D1 | 50.00 ± 44.10 | -16.67 ± NA |
| Jaundice: Change at C11 D1 | 16.67 ± 44.10 | -83.33 ± NA |
| Body Image: Change at C11 D1 | 50.00 ± 44.10 | 16.67 ± NA |
| Health Care Satisfaction: Change at C11 D1 | 27.78 ± 25.46 | -16.67 ± NA |
| Sexual Functioning: Change at C11 D1 | -33.33 ± 47.14 | -33.33 ± NA |
| Ascites: Change at C11 D1 | 22.22 ± 38.49 | 33.33 ± NA |
| Indigestion: Change at C11 D1 | 11.11 ± 19.25 | 0.00 ± NA |
| Flatulence: Change at C11 D1 | 11.11 ± 19.25 | 0.00 ± NA |
| Cachexia: Change at C11 D1 | 55.56 ± 25.46 | 16.67 ± NA |
| Side Effects: Change at C11 D1 | 55.56 ± 50.92 | 11.11 ± NA |
| Fear of Future Health: Change at C11 D1 | 0.00 ± 0.00 | 33.33 ± NA |
| Ability to Plan Future: Change at C11 D1 | 44.44 ± 50.92 | 66.67 ± NA |
| Pancreatic Pain: Change at C12 D1 | -5.56 ± 20.97 | — |
| Eating Related Items: Change at C12 D1 | 16.67 ± 16.67 | — |
| Altered Bowel Habits: Change at C12 D1 | 27.78 ± 34.69 | — |
| Jaundice: Change at C12 D1 | 0.00 ± 0.00 | — |
| Body Image: Change at C12 D1 | 16.67 ± 16.67 | — |
| Health Care Satisfaction: Change at C12 D1 | -5.56 ± 41.94 | — |
| Sexual Functioning: Change at C12 D1 | 0.00 ± 66.67 | — |
| Ascites: Change at C12 D1 | -22.22 ± 19.25 | — |
| Indigestion: Change at C12 D1 | 0.00 ± 0.00 | — |
| Flatulence: Change at C12 D1 | 0.00 ± 0.00 | — |
| Cachexia: Change at C12 D1 | 33.33 ± 28.87 | — |
| Side Effects: Change at C12 D1(n=3,0) | 33.33 ± 40.06 | — |
| Fear of Future Health: Change at C12 D1 | 0.00 ± 0.00 | — |
| Ability to Plan Future: Change at C12 D1 | 0.00 ± 0.00 | — |
| Pancreatic Pain: Change at C13 D1 | 20.83 ± 5.89 | — |
| Eating Related Items: Change at C13 D1 | 58.33 ± 58.93 | — |
| Altered Bowel Habits: Change at C13 D1 | 8.33 ± 11.79 | — |
| Jaundice: Change at C13 D1 | 25.00 ± 35.36 | — |
| Body Image: Change at C13 D1 | 41.67 ± 58.93 | — |
| Health Care Satisfaction: Change at C13 D1 | -16.67 ± 23.57 | — |
| Sexual Functioning: Change at C13 D1 | -50.00 ± 23.57 | — |
| Ascites: Change at C13 D1 | 16.67 ± 23.57 | — |
| Indigestion: Change at C13 D1 | 0.00 ± 0.00 | — |
| Flatulence: Change at C13 D1 | 16.67 ± 23.57 | — |
| Cachexia: Change at C13 D1 | 33.33 ± 47.14 | — |
| Side Effects: Change at C13 D1 | 16.67 ± 7.86 | — |
| Fear of Future Health: Change at C13 D1 | 0.00 ± 0.00 | — |
| Ability to Plan Future: Change at C13 D1 | 16.67 ± 23.57 | — |
| Pancreatic Pain: Change at C14 D1 | -8.33 ± NA | — |
| Eating Related Items: Change at C14 D1 | 16.67 ± NA | — |
| Altered Bowel Habits: Change at C14 D1 | 33.33 ± NA | — |
| Jaundice: Change at C14 D1 | 33.33 ± NA | — |
| Body Image: Change at C14 D1 | 33.33 ± NA | — |
| Health Care Satisfaction: Change at C14 D1 | 0.00 ± NA | — |
| Sexual Functioning: Change at C14 D1 | -33.33 ± NA | — |
| Ascites: Change at C14 D1 | 0.00 ± NA | — |
| Indigestion: Change at C14 D1 | 0.00 ± NA | — |
| Flatulence: Change at C14 D1 | 33.33 ± NA | — |
| Cachexia: Change at C14 D1 | 50.00 ± NA | — |
| Side Effects: Change at C14 D1 | 0.00 ± NA | — |
| Fear of Future Health: Change at C14 D1 | 0.00 ± NA | — |
| Ability to Plan Future: Change at C14 D1 | 0.00 ± NA | — |
| Pancreatic Pain: Change at EoS | 58.33 ± 35.36 | 0.00 ± NA |
| Eating Related Items: Change at EoS | 25.00 ± 82.50 | 0.00 ± NA |
| Altered Bowel Habits: Change at EoS | 83.33 ± 23.57 | 0.00 ± NA |
| Jaundice: Change at EoS | 8.33 ± 11.79 | 0.00 ± NA |
| Body Image: Change at EoS | 66.67 ± 0.00 | -16.67 ± NA |
| Health Care Satisfaction: Change at EoS | 0.00 ± NA | 33.33 ± NA |
| Sexual Functioning: Change at EoS | 0.00 ± NA | 33.33 ± NA |
| Ascites: Change at EoS | 33.33 ± 47.14 | 33.33 ± NA |
| Indigestion: Change at EoS | 33.33 ± 47.14 | 33.33 ± NA |
| Flatulence: Change at EoS | 83.33 ± 23.57 | 0.00 ± NA |
| Cachexia: Change at EoS | 66.67 ± 0.00 | 0.00 ± NA |
| Side Effects: Change at EoS | 19.44 ± 90.35 | -11.11 ± NA |
| Fear of Future Health: Change at EoS | 33.33 ± NA | -33.33 ± NA |
| Ability to Plan Future: Change at EoS | 66.67 ± NA | 33.33 ± NA |
Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Axitinib + Gemcitabine (Phase 1 Lead-In) | — | 3/8 (37.5%) | 7/8 (87.5%) |
| Axitinib + Gemcitabine | — | 35/68 (51.5%) | 67/68 (98.5%) |
| Gemcitabine | — | 10/31 (32.3%) | 26/31 (83.9%) |
| Event | Axitinib + Gemcitabine (Phase 1 Lead-In) | Axitinib + Gemcitabine | Gemcitabine |
|---|---|---|---|
| AnaemiaBlood and lymphatic system disorders | 1/8 | 4/68 | 1/31 |
| TinnitusEar and labyrinth disorders | 1/8 | 0/68 | 0/31 |
| Multi-organ failureGeneral disorders | 1/8 | 0/68 | 0/31 |
| InfectionInfections and infestations | 1/8 | 0/68 | 0/31 |
| Platelet count decreasedInvestigations | 1/8 | 0/68 | 0/31 |
| PyrexiaGeneral disorders | 0/8 | 1/68 | 3/31 |
| Disease progressionGeneral disorders | 0/8 | 6/68 | 0/31 |
| DyspnoeaRespiratory, thoracic and mediastinal disorders | 0/8 | 6/68 | 0/31 |
| Abdominal painGastrointestinal disorders | 0/8 | 5/68 | 0/31 |
| NauseaGastrointestinal disorders | 0/8 | 2/68 | 2/31 |
| Event | Axitinib + Gemcitabine (Phase 1 Lead-In) | Axitinib + Gemcitabine | Gemcitabine |
|---|---|---|---|
| FatigueGeneral disorders | 7/8 | 29/68 | 10/31 |
| DiarrhoeaGastrointestinal disorders | 4/8 | 35/68 | 8/31 |
| AnaemiaBlood and lymphatic system disorders | 4/8 | 16/68 | 7/31 |
| ThrombocytopeniaBlood and lymphatic system disorders | 4/8 | 10/68 | 2/31 |
| HypertensionVascular disorders | 4/8 | 16/68 | 0/31 |
| NauseaGastrointestinal disorders | 3/8 | 30/68 | 15/31 |
| VomitingGastrointestinal disorders | 2/8 | 29/68 | 12/31 |
| Decreased appetiteMetabolism and nutrition disorders | 1/8 | 29/68 | 10/31 |
| Mucosal inflammationGeneral disorders | 3/8 | 12/68 | 2/31 |
| Cytolytic hepatitisHepatobiliary disorders | 3/8 | 1/68 | 1/31 |
| Age, Customized(Participants) | Axitinib + Gemcitabine (Phase 1 Lead-In) | Axitinib + Gemcitabine | Gemcitabine | Total |
|---|---|---|---|---|
| 18 years to 44 years | 0 | 2 | 4 | 6 |
| 45 years to 64 years | 5 | 31 | 20 | 56 |
| Greater than or equal to 65 years | 3 | 36 | 10 | 49 |
| Sex: Female, Male(Participants) | Axitinib + Gemcitabine (Phase 1 Lead-In) | Axitinib + Gemcitabine | Gemcitabine | Total |
|---|---|---|---|---|
| Female | 1 | 34 | 18 | 53 |
| Male | 7 | 35 | 16 | 58 |
Plan to share: Yes — Pfizer will provide access to individual de-identified participant data and related study documents (e.g. protocol, Statistical Analysis Plan (SAP), Clinical Study Report (CSR)) upon request from qualified researchers, and subject to certain criteria, conditions, and exceptions. Further details on Pfizer's data sharing criteria and process for requesting access can be found at: https://www.pfizer.com/science/clinical_trials/trial_data_and_results/data_requests.
Data sharing details ↗ · www.pfizer.com
Ran from Jul 2005 to primary completion in Mar 2008, 32 months.
Results were first posted in Aug 2012, 4 years 5 months after primary completion. A results delay was requested in Mar 2009.
Of 69 industry-sponsored phase 2 interventional studies under Pancreatic Neoplasms, half reached primary completion within 36 months of starting (the median), counting those still running; a quarter within 26 and three quarters within 68. This study's 32 months is below that.
Counting every sponsor, half of 394 studies reached it within 57 months; a quarter within 35 and three quarters within 80.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Apr 2019. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Axitinib